20:36 , Feb 23, 2018 |  BC Week In Review  |  Company News

Arix, Fosun in China-focused deal

Life sciences investment firm Arix Bioscience plc (LSE:ARIX) partnered with Fosun International Ltd. (HKSE:656) to invest in and build newcos focused on the China market. The deal will give Arix access to investment opportunities in China,...
15:25 , Feb 23, 2018 |  BC Week In Review  |  Company News

Ipsen seeks to invest in early stage innovation with Arix

Life sciences investment firm Arix Bioscience plc (LSE:ARIX) partnered with Ipsen Group (Euronext:IPN; Pink:IPSEY) to create new companies focused on developing and commercializing "innovative therapies" in undisclosed indications. Arix declined to disclose further details about...
23:28 , Feb 21, 2018 |  BC Extra  |  Company News

Ipsen seeks to invest in early stage innovation with Arix

Life sciences investment firm Arix Bioscience plc (LSE:ARIX) partnered with Ipsen Group (Euronext:IPN; Pink:IPSEY) to create new companies focused on developing and commercializing "innovative therapies" in undisclosed indications. Arix said it could not provide details...
17:29 , Feb 20, 2018 |  BC Extra  |  Company News

Arix, Fosun in China-focused deal

Life sciences investment firm Arix Bioscience plc (LSE:ARIX) partnered with Fosun International Ltd. (HKSE:656) to invest in and build newcos focused on the China market. The deal will give Arix access to investment opportunities in...
20:10 , Apr 24, 2017 |  BC Extra  |  Company News

UCB reveals CRL for Cimzia

UCB S.A. (Euronext:UCB) revealed in its 1Q17 earnings report that FDA issued a complete response letter last month for Cimzia certolizumab pegol to treat polyarticular juvenile idiopathic arthritis. UCB said the letter concerns the reliability...
00:01 , Apr 22, 2017 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 26 biotechs and pharmas are expected to report earnings this week. (A) Fiscal 2Q; (B) Fiscal 4Q; (C) 12-month EPS CompanyDatePre/post mkt1Q17 EPS est1Q16 EPSExpected chgUCB Group (Euronext:UCB)4/24PreNANANABiogen Inc. (NASDAQ:BIIB)4/25Pre$5.00$4.794%Eli Lilly and...
16:31 , Apr 14, 2017 |  BC Week In Review  |  Company News

UCB, Q-State deal

UCB and Q-State partnered to discover and develop therapeutics against undisclosed genetic targets to treat epilepsy subtypes, including genetically defined childhood epilepsy. Q-State will apply its proprietary Optopatch platform to build disease models and characterize...
22:45 , Apr 7, 2017 |  BioCentury  |  Finance

To market, to market

Investors are hoping that a slew of approvals and data readouts can maintain biotech’s momentum on the heels of several high-profile successes that came just before or after 1Q’s end. Chief among those was Vertex...
19:48 , Mar 10, 2017 |  BC Extra  |  Company News

FDA extends review of Radius' osteoporosis candidate

Radius Health Inc. (NASDAQ:RDUS) slipped $2.26 to $40.85 on Friday after it said FDA delayed by three months the PDUFA date for abaloparatide-SC (BA058-SC), which it is reviewing to treat postmenopausal osteoporosis. The new PDUFA...
20:15 , Feb 24, 2017 |  BioCentury  |  Finance

IPO for evergreen

A year after launching with an initial £52 million ($64.8 million), investment company Arix Bioscience plc (LSE:ARIX) has added £100 million ($125.2 million) to its coffers to support up to 15 direct investments across the...